Kidney Cancer
Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Velcheti Evaluates Activity of Repotrectinib for ROS1 Fusion–Positive NSCLC
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for repotrectinib in non–small cell lung cancer.
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
First Patient Dosed in IB-T101 ccRCC Trial
IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma treatment in a dose-escalation trial.
Casdatifan Shows Promise in Treating Clear Cell Renal Cell Carcinoma
Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.
